{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:06:29Z","timestamp":1789383989767,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40487-026-00463-6","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:03:34Z","timestamp":1787677414000},"page":"939-966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Reported Outcome Instruments in Non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review"],"prefix":"10.1007","volume":"14","author":[{"given":"Ingolf","family":"Griebsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-7120","authenticated-orcid":false,"given":"Sunil","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C.","family":"Gotay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"3","key":"463_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et\u00a0al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660. (Epub 20210204. PubMed PMID: 33538338).","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"463_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00345-024-04949-8","volume":"42","author":"A W\u00e9ber","year":"2024","unstructured":"W\u00e9ber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P, et\u00a0al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024;42(1):237. https:\/\/doi.org\/10.1007\/s00345-024-04949-8. (Epub 20240416. PubMed PMID: 38625417; PubMed Central PMCID: PMCPMC11021283).","journal-title":"World J Urol"},{"issue":"6","key":"463_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1097\/ju.0000000000001633","volume":"205","author":"JT Matulay","year":"2021","unstructured":"Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, et\u00a0al. Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette\u2013Gu\u00e9rin: implications for clinical trial design. J Urol. 2021;205(6):1612\u201321. https:\/\/doi.org\/10.1097\/ju.0000000000001633. (Epub 20210127. PubMed PMID: 33502236).","journal-title":"J Urol"},{"issue":"3","key":"463_CR4","doi-asserted-by":"publisher","first-page":"106.e1","DOI":"10.1016\/j.urolonc.2021.10.008","volume":"40","author":"Z Dovey","year":"2022","unstructured":"Dovey Z, Pfail J, Martini A, Steineck G, Dey L, Renstr\u00f6m L, et\u00a0al. Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. Urol Oncol. 2022;40(3):106.e1\u2013e10. https:\/\/doi.org\/10.1016\/j.urolonc.2021.10.008. (Epub 20211125. PubMed PMID: 34840075).","journal-title":"Urol Oncol"},{"key":"463_CR5","doi-asserted-by":"publisher","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, Henne C, Mariappan P, Geiges G, P\u00f6hlmann J, Pollock RF. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124. https:\/\/doi.org\/10.3389\/fonc.2023.1170124. (Epub 20230602. PubMed PMID: 37333804; PubMed Central PMCID: PMCPMC10272547).","journal-title":"Front Oncol"},{"key":"463_CR6","unstructured":"USFDA. Patient-reported outcome measures: use in medical product development to support labeling claims: USFDA; 2009 [cited 2025 August 26]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims."},{"key":"463_CR7","unstructured":"EMA. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man\u2014the use of patient-reported outcome (PRO) measures in oncology studies\u2014scientific guideline 2016 [cited 2025 August 26]. https:\/\/www.ema.europa.eu\/en\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man-use-patient-reported-outcome-pro-measures-oncology-studies-scientific-guideline."},{"key":"#cr-split#-463_CR8.1","unstructured":"Group HC. Guidance on outcomes for joint clinical assessments. Adopted on 10 June 2024 by the HTA CG pursuant to Article 3(7), point (d), of Regulation"},{"key":"#cr-split#-463_CR8.2","unstructured":"(EU) 2021\/2282 on Health Technology Assessment 2024 [cited 2025 September 17]. https:\/\/health.ec.europa.eu\/document\/download\/a70a62c7-325c-401e-ba42-66174b656ab8_en?filename=hta_outcomes_jca_guidance_en.pdf."},{"key":"463_CR9","unstructured":"USFDA. Core patient-reported outcomes in cancer clinical trials. Guidance for Industry: USFDA; 2024 [cited 2025 September 15]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials."},{"issue":"6","key":"463_CR10","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","volume":"66","author":"JM Blazeby","year":"2014","unstructured":"Blazeby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD, et\u00a0al. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol. 2014;66(6):1148\u201356. https:\/\/doi.org\/10.1016\/j.eururo.2014.02.034. (Epub 20140225. PubMed PMID: 24612661; PubMed Central PMCID: PMCPMC4410297).","journal-title":"Eur Urol"},{"issue":"5","key":"463_CR11","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.juro.2010.01.013","volume":"183","author":"SM Gilbert","year":"2010","unstructured":"Gilbert SM, Dunn RL, Hollenbeck BK, Montie JE, Lee CT, Wood DP, et\u00a0al. Development and validation of the bladder cancer index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol. 2010;183(5):1764\u20139. https:\/\/doi.org\/10.1016\/j.juro.2010.01.013. (Epub 20100317. PubMed PMID: 20299056).","journal-title":"J Urol"},{"issue":"11","key":"463_CR12","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1007\/s00520-019-04709-0","volume":"27","author":"A Degboe","year":"2019","unstructured":"Degboe A, Ivanescu C, Rohay JM, Turner RR, Cella D. Validity and performance of the functional assessment of cancer therapy-bladder (FACT-Bl) among advanced urothelial cancer patients. Support Care Cancer. 2019;27(11):4189\u201398. https:\/\/doi.org\/10.1007\/s00520-019-04709-0. (Epub 20190301. PubMed PMID: 30825026; PubMed Central PMCID: PMCPMC6803583).","journal-title":"Support Care Cancer"},{"issue":"5","key":"463_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et\u00a0al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365. (PubMed PMID: 8433390).","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"463_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/jco.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et\u00a0al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570\u20139. https:\/\/doi.org\/10.1200\/jco.1993.11.3.570. (PubMed PMID: 8445433).","journal-title":"J Clin Oncol"},{"key":"463_CR15","doi-asserted-by":"publisher","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):1\u201311. https:\/\/doi.org\/10.1093\/jnci\/dju244. (Epub 20140929. PubMed PMID: 25265940; PubMed Central PMCID: PMCPMC4200059).","DOI":"10.1093\/jnci\/dju244"},{"key":"463_CR16","doi-asserted-by":"publisher","unstructured":"Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et\u00a0al. Assessing symptom distress in cancer patients: the M.D. Anderson symptom inventory. Cancer. 2000;89(7):1634\u201346. https:\/\/doi.org\/10.1002\/1097-0142(20001001)89:7&lt;1634::aid-cncr29&gt;3.0.co;2-v (PubMed PMID: 11013380).","DOI":"10.1002\/1097-0142(20001001)89:7&lt;1634::aid-cncr29&gt;3.0.co;2-v"},{"issue":"2","key":"463_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11136-020-02637-9","volume":"30","author":"C Rutherford","year":"2021","unstructured":"Rutherford C, Patel MI, Tait MA, Smith DP, Costa DSJ, Sengupta S, et\u00a0al. Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. Qual Life Res. 2021;30(2):345\u201366. https:\/\/doi.org\/10.1007\/s11136-020-02637-9. (Epub 20200922. PubMed PMID: 32960394).","journal-title":"Qual Life Res"},{"issue":"10","key":"463_CR18","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1007\/s00520-017-3717-5","volume":"25","author":"C Rutherford","year":"2017","unstructured":"Rutherford C, Costa DSJ, King MT, Smith DP, Patel MI. A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer. Support Care Cancer. 2017;25(10):3095\u2013102. https:\/\/doi.org\/10.1007\/s00520-017-3717-5. (Epub 20170427. PubMed PMID: 28451912).","journal-title":"Support Care Cancer"},{"issue":"5","key":"463_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/cncr.31133","volume":"124","author":"TP Pearman","year":"2018","unstructured":"Pearman TP, Beaumont JL, Mroczek D, O\u2019Connor M, Cella D. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer. 2018;124(5):991\u20137. https:\/\/doi.org\/10.1002\/cncr.31133. (Epub 20171113. PubMed PMID: 29131323; PubMed Central PMCID: PMCPMC5892190).","journal-title":"Cancer"},{"issue":"10","key":"463_CR20","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s11136-024-03740-x","volume":"33","author":"C Arizmendi","year":"2024","unstructured":"Arizmendi C, Zhu Y, Khan M, Gable J, Reeve BB, King-Kallimanis B, et\u00a0al. The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments. Qual Life Res. 2024;33(10):2869\u201380. https:\/\/doi.org\/10.1007\/s11136-024-03740-x. (Epub 20240724. PubMed PMID: 39046616; PubMed Central PMCID: PMCPMC11452438).","journal-title":"Qual Life Res"},{"key":"463_CR21","unstructured":"EORTC. Evidence generation for side effect burden item Q168: EORTC; [cited 2025 August 27]. https:\/\/qol.eortc.org\/projectqol\/evidence-generation-for-side-effect-burden-item-q168\/."},{"issue":"1","key":"463_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-024-00823-8","volume":"8","author":"A Regnault","year":"2024","unstructured":"Regnault A, Bunod L, Loubert A, Brose MS, Hess LM, Maeda P, et\u00a0al. Assessing tolerability with the functional assessment of cancer therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. J Patient-Rep Outcomes. 2024;8(1):149. https:\/\/doi.org\/10.1186\/s41687-024-00823-8.","journal-title":"J Patient-Rep Outcomes"},{"key":"463_CR23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71. (Epub 20210329. PubMed PMID: 33782057; PubMed Central PMCID: PMCPMC8005924).","journal-title":"BMJ"},{"issue":"4","key":"463_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","volume":"19","author":"LB Mokkink","year":"2010","unstructured":"Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et\u00a0al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539\u201349. https:\/\/doi.org\/10.1007\/s11136-010-9606-8. (Epub 20100219. PubMed PMID: 20169472; PubMed Central PMCID: PMCPMC2852520).","journal-title":"Qual Life Res"},{"issue":"5","key":"463_CR25","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s11136-017-1765-4","volume":"27","author":"LB Mokkink","year":"2018","unstructured":"Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, et\u00a0al. COSMIN Risk of Bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1171\u20139. https:\/\/doi.org\/10.1007\/s11136-017-1765-4. (Epub 20171219. PubMed PMID: 29260445; PubMed Central PMCID: PMCPMC5891552).","journal-title":"Qual Life Res"},{"issue":"1","key":"463_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4143\/crt.2016.594","volume":"50","author":"J Park","year":"2018","unstructured":"Park J, Shin DW, Kim TH, Jung SI, Nam JK, Park SC, et\u00a0al. Development and validation of the Korean version of the European organization for research and treatment of cancer quality of life questionnaire for patients with non-muscle invasive bladder cancer: EORTC QLQ-NMIBC24. Cancer Res Treat. 2018;50(1):40\u20139. https:\/\/doi.org\/10.4143\/crt.2016.594. (Epub 20170310. PubMed PMID: 28279061; PubMed Central PMCID: PMCPMC5784644).","journal-title":"Cancer Res Treat"},{"issue":"1","key":"463_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s41687-021-00372-4","volume":"5","author":"TM Ripping","year":"2021","unstructured":"Ripping TM, Westhoff E, Aaronson NK, Van Hemelrijck M, Rammant E, Witjes JA, et\u00a0al. Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire module for patients with non-muscle-invasive bladder cancer. J Patient Rep Outcomes. 2021;5(1):96. https:\/\/doi.org\/10.1186\/s41687-021-00372-4. (Epub 20210920. PubMed PMID: 34542736; PubMed Central PMCID: PMCPMC8452806).","journal-title":"J Patient Rep Outcomes"},{"key":"463_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","volume":"178","author":"K Cocks","year":"2023","unstructured":"Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, et\u00a0al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer. 2023;178:128\u201338. https:\/\/doi.org\/10.1016\/j.ejca.2022.10.026. (Epub 20221101. PubMed PMID: 36436330).","journal-title":"Eur J Cancer"},{"issue":"6","key":"463_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.purol.2011.12.004","volume":"22","author":"N Gaunez","year":"2010","unstructured":"Gaunez N, Larr\u00e9 S, Pir\u00e8s C, Dor\u00e9 B, Wei J, Pfister C, et\u00a0al. French translation and linguistic validation of the questionnaire bladder cancer index (BCI). Prog Urol. 2010;22(6):350\u20133. https:\/\/doi.org\/10.1016\/j.purol.2011.12.004. (Epub 20120120. PubMed PMID: 22541905).","journal-title":"Prog Urol"},{"issue":"3","key":"463_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12253-014-9866-7","volume":"21","author":"NV Hev\u00e9r","year":"2015","unstructured":"Hev\u00e9r NV, P\u00e9ntek M, Ball\u00f3 A, Gul\u00e1csi L, Baji P, Brodszky V, et\u00a0al. Health related quality of life in patients with bladder cancer: a cross-sectional survey and validation study of the Hungarian version of the bladder cancer index. Pathol Oncol Res. 2015;21(3):619\u201327. https:\/\/doi.org\/10.1007\/s12253-014-9866-7. (Epub 20141201. PubMed PMID: 25434791).","journal-title":"Pathol Oncol Res"},{"issue":"12","key":"463_CR31","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s10147-020-01770-2","volume":"25","author":"T Osawa","year":"2020","unstructured":"Osawa T, Wei JT, Abe T, Honda M, Yamada S, Furumido J, et\u00a0al. Health-related quality of life in Japanese patients with bladder cancer measured by a newly developed Japanese version of the bladder cancer index. Int J Clin Oncol. 2020;25(12):2090\u20138. https:\/\/doi.org\/10.1007\/s10147-020-01770-2. (Epub 20200824. PubMed PMID: 32833102; PubMed Central PMCID: PMCPMC7677272).","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"463_CR32","doi-asserted-by":"publisher","first-page":"e27487","DOI":"10.7759\/cureus.27487","volume":"14","author":"A Pervaiz","year":"2022","unstructured":"Pervaiz A, Ather MH, Bashir A, Aziz W. Urdu translation and linguistic validation of the bladder cancer index questionnaire. Cureus. 2022;14(7):e27487. https:\/\/doi.org\/10.7759\/cureus.27487. (Epub 20220730. PubMed PMID: 36060374; PubMed Central PMCID: PMCPMC9423128).","journal-title":"Cureus"},{"issue":"1","key":"463_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-20","volume":"12","author":"S Schmidt","year":"2014","unstructured":"Schmidt S, Riel R, Frances A, Lorente Garin JA, Bonfill X, Martinez-Zapata MJ, et\u00a0al. Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation. Health Qual Life Outcomes. 2014;12(1):20. https:\/\/doi.org\/10.1186\/1477-7525-12-20.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"463_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.afju.2017.09.007","volume":"24","author":"I Ziouziou","year":"2018","unstructured":"Ziouziou I, Touzani MA, Karmouni T, El Khader K, Koutani A, Attya Andaloussi AI. Arabic translation and linguistic validation of the questionnaire bladder cancer index. Afr J Urol. 2018;24(2):104\u20137. https:\/\/doi.org\/10.1016\/j.afju.2017.09.007.","journal-title":"Afr J Urol"},{"issue":"4","key":"463_CR35","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1007\/s00520-022-06802-3","volume":"30","author":"P Griffiths","year":"2022","unstructured":"Griffiths P, Peipert JD, Leith A, Rider A, Morgan L, Cella D, et\u00a0al. Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. Support Care Cancer. 2022;30(4):3613\u201323. https:\/\/doi.org\/10.1007\/s00520-022-06802-3. (Epub 20220114. PubMed PMID: 35031830; PubMed Central PMCID: PMCPMC8857159).","journal-title":"Support Care Cancer"},{"issue":"1","key":"463_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-025-00864-7","volume":"9","author":"C Rutherford","year":"2025","unstructured":"Rutherford C, Tait M-A, Costa DSJ, King MT, Smith DP, Sengupta S, et\u00a0al. Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI. J Patient Report Outcomes. 2025;9(1):36. https:\/\/doi.org\/10.1186\/s41687-025-00864-7.","journal-title":"J Patient Report Outcomes"},{"issue":"1","key":"463_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s41687-019-0141-2","volume":"3","author":"GA Taarnh\u00f8j","year":"2019","unstructured":"Taarnh\u00f8j GA, Lindberg H, Johansen C, Pappot H. Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy. J Patient Rep Outcomes. 2019;3(1):56. https:\/\/doi.org\/10.1186\/s41687-019-0141-2. (Epub 20190822. PubMed PMID: 31440865; PubMed Central PMCID: PMCPMC6706489).","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"463_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11115-7","volume":"23","author":"M G\u00fcnther","year":"2023","unstructured":"G\u00fcnther M, Hentschel L, Schuler M, M\u00fcller T, Sch\u00fctte K, Ko Y-D, et\u00a0al. Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers. BMC Cancer. 2023;23(1):629. https:\/\/doi.org\/10.1186\/s12885-023-11115-7.","journal-title":"BMC Cancer"},{"issue":"8","key":"463_CR39","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et\u00a0al. Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2639. (PubMed PMID: 26270597; PubMed Central PMCID: PMCPMC4857599).","journal-title":"JAMA Oncol"},{"issue":"5","key":"463_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","volume":"79","author":"JWF Catto","year":"2021","unstructured":"Catto JWF, Downing A, Mason S, Wright P, Absolom K, Bottomley S, et\u00a0al. Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur Urol. 2021;79(5):621\u201332. https:\/\/doi.org\/10.1016\/j.eururo.2021.01.032. (Epub 20210210. PubMed PMID: 33581875; PubMed Central PMCID: PMCPMC8082273).","journal-title":"Eur Urol"},{"issue":"8","key":"463_CR41","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1007\/s11255-025-04418-0","volume":"57","author":"V Iossa","year":"2025","unstructured":"Iossa V, Olivieri A, Buonopane R, Di Girolamo A, Fiore F, Sessa G, et\u00a0al. Assessment of quality of life in patients undergoing hyperthermic intravesical chemotherapy (HIVEC) using EORTC questionnaires (QLQ-C30 and QLQ-NMIBC24). Int Urol Nephrol. 2025;57(8):2415\u201323. https:\/\/doi.org\/10.1007\/s11255-025-04418-0. (Epub 20250217. PubMed PMID: 39960577).","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"463_CR42","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jsxm.2022.06.016","volume":"19","author":"I Jubber","year":"2022","unstructured":"Jubber I, Rogers Z, Catto JW, Bottomley S, Glaser A, Downing A, et\u00a0al. Sexual activity, function and dysfunction after a diagnosis of bladder cancer. J Sex Med. 2022;19(9):1431\u201341. https:\/\/doi.org\/10.1016\/j.jsxm.2022.06.016. (Epub 20220721. PubMed PMID: 35871051).","journal-title":"J Sex Med"},{"issue":"3","key":"463_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3109\/21681805.2015.1132762","volume":"50","author":"K Mogensen","year":"2016","unstructured":"Mogensen K, Christensen KB, Vrang ML, Hermann GG. Hospitalization for transurethral bladder resection reduces quality of life in Danish patients with non-muscle-invasive bladder tumour. Scand J Urol. 2016;50(3):170\u20134. https:\/\/doi.org\/10.3109\/21681805.2015.1132762. (Epub 20160127. PubMed PMID: 26817989).","journal-title":"Scand J Urol"},{"key":"463_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.euros.2024.02.018","volume":"63","author":"FR Schroeck","year":"2024","unstructured":"Schroeck FR, Grubb R, MacKenzie TA, Ould Ismail AA, Jensen L, Tsongalis GJ, et\u00a0al. Clinical trial protocol for \u201cReplace Cysto\u201d: replacing invasive cystoscopy with urine testing for non-muscle-invasive bladder cancer surveillance-A multicenter, randomized, phase 2 healthcare delivery trial comparing quality of life during cancer surveillance with Xpert bladder cancer monitor or bladder EpiCheck urine testing versus frequent cystoscopy. Eur Urol Open Sci. 2024;63:19\u201330. https:\/\/doi.org\/10.1016\/j.euros.2024.02.018. (Epub 20240321. PubMed PMID: 38558761; PubMed Central PMCID: PMCPMC10981003).","journal-title":"Eur Urol Open Sci"},{"key":"463_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2340\/sju.v60.44187","volume":"60","author":"RV Milling","year":"2025","unstructured":"Milling RV, Nielsen NK, Graugaard-Jensen C, Christensen P, Pappot H, Jensen JB. Long-term effect of treatment for non-muscle invasive bladder cancer on quality of life: a cross-sectional study. Scand J Urol. 2025;60:141\u20137. https:\/\/doi.org\/10.2340\/sju.v60.44187. (Epub 20250727. PubMed PMID: 40714886).","journal-title":"Scand J Urol"},{"issue":"4","key":"463_CR46","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.euo.2023.11.007","volume":"7","author":"I Beeren","year":"2024","unstructured":"Beeren I, Klerks NE, Aben KK, Oddens JR, Witjes JA, Kiemeney LA, et\u00a0al. Health-related quality of life during the first 4\u00a0years after non-muscle-invasive bladder cancer diagnosis: results of a large multicentre prospective cohort. Eur Urol Oncol. 2024;7(4):829\u201337. https:\/\/doi.org\/10.1016\/j.euo.2023.11.007. (Epub 20231122. PubMed PMID: 37996278).","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"463_CR47","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00345-025-05726-x","volume":"43","author":"HS Menold","year":"2025","unstructured":"Menold HS, Gruene B, Koenig J, Lenhart M, Waldbillig F, Kowalewski KF, et\u00a0al. Impact of transurethral resection of bladder tumors on sexual function and quality of life using ePROMs in patients with bladder cancer\u2014a prospective cohort study. World J Urol. 2025;43(1):370. https:\/\/doi.org\/10.1007\/s00345-025-05726-x. (Epub 20250610. PubMed PMID: 40495081; PubMed Central PMCID: PMCPMC12152061).","journal-title":"World J Urol"},{"issue":"4","key":"463_CR48","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.juro.2018.10.008","volume":"201","author":"CC Peyton","year":"2019","unstructured":"Peyton CC, Henriksen C, Reich RR, Azizi M, Gilbert SM. Estimating minimally important differences for the bladder cancer index using distribution and anchor based approaches. J Urol. 2019;201(4):709\u201314. https:\/\/doi.org\/10.1016\/j.juro.2018.10.008. (PubMed PMID: 30342063; PubMed Central PMCID: PMCPMC7811779).","journal-title":"J Urol"},{"issue":"11","key":"463_CR49","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/jjco\/hyl094","volume":"36","author":"E Kikuchi","year":"2006","unstructured":"Kikuchi E, Horiguchi Y, Nakashima J, Ohigashi T, Oya M, Nakagawa K, et\u00a0al. Assessment of long-term quality of life using the FACT-BL questionnaire in patients with an ileal conduit, continent reservoir, or orthotopic neobladder. Jpn J Clin Oncol. 2006;36(11):712\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyl094. (Epub 20061003. PubMed PMID: 17018576).","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"463_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.acuro.2015.12.001","volume":"40","author":"I Ab\u00e1igar-Pedraza","year":"2016","unstructured":"Ab\u00e1igar-Pedraza I, Meg\u00edas-Garrig\u00f3s J, S\u00e1nchez-Pay\u00e1 J. Quality-of-life survey for patients diagnosed with nonmuscle-invasive bladder cancer. Actas Urol Esp. 2016;40(4):251\u20137. https:\/\/doi.org\/10.1016\/j.acuro.2015.12.001. (Epub 20160113. PubMed PMID: 26794624).","journal-title":"Actas Urol Esp"},{"issue":"2","key":"463_CR51","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.aju.2017.01.008","volume":"15","author":"MH Zahran","year":"2017","unstructured":"Zahran MH, Sheir K, Zidan EM, Ali-El-Dein B. Validation of the Arabic version of the functional assessment of cancer therapy-bladder questionnaire in Egyptian patients with bladder cancer. Arab J Urol. 2017;15(2):110\u20134. https:\/\/doi.org\/10.1016\/j.aju.2017.01.008. (Epub 20170425. PubMed PMID: 29071139; PubMed Central PMCID: PMCPMC5653643).","journal-title":"Arab J Urol"},{"key":"463_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euros.2023.08.004","volume":"56","author":"C van Straten","year":"2023","unstructured":"van Straten C, Caris C, Grimm MO, Colombel M, Muilwijk T, Mart\u00ednez-Pi\u00f1eiro L, et\u00a0al. Quality of life in patients with high-grade non-muscle-invasive bladder cancer undergoing standard versus reduced frequency of Bacillus Calmette\u2013Gu\u00e9rin instillations: the EAU-RF NIMBUS trial. Eur Urol Open Sci. 2023;56:15\u201324. https:\/\/doi.org\/10.1016\/j.euros.2023.08.004. (Epub 20230912. PubMed PMID: 37822514; PubMed Central PMCID: PMCPMC10562176).","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"463_CR53","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00520-012-1680-8","volume":"21","author":"S Singer","year":"2013","unstructured":"Singer S, Ziegler C, Schwalenberg T, Hinz A, G\u00f6tze H, Schulte T. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer. 2013;21(5):1383\u201393. https:\/\/doi.org\/10.1007\/s00520-012-1680-8. (Epub 20121214. PubMed PMID: 23238655).","journal-title":"Support Care Cancer"},{"key":"463_CR54","doi-asserted-by":"publisher","first-page":"101044","DOI":"10.1016\/j.conctc.2022.101044","volume":"30","author":"SP Psutka","year":"2022","unstructured":"Psutka SP, Veleber S, Siman J, Jannat S, Holt S, Wright JL, et\u00a0al. Effects of acupuncture to decrease adverse events in patients with high-risk non-muscle invasive bladder cancer receiving induction intravesical BCG therapy: study protocol for a randomized, controlled pilot and feasibility study. Contemp Clin Trials Commun. 2022;30:101044. https:\/\/doi.org\/10.1016\/j.conctc.2022.101044. (Epub 20221205. PubMed PMID: 36561732; PubMed Central PMCID: PMCPMC9763430).","journal-title":"Contemp Clin Trials Commun"},{"issue":"5","key":"463_CR55","first-page":"9480","volume":"25","author":"S Siracusano","year":"2018","unstructured":"Siracusano S, Silvestri T, Bassi S, Porcaro AB, Cerruto MA, Talamini R, et\u00a0al. Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer. Can J Urol. 2018;25(5):9480\u20135 (PubMed PMID: 30281005).","journal-title":"Can J Urol"},{"issue":"3","key":"463_CR56","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","volume":"190","author":"P Gontero","year":"2013","unstructured":"Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, et\u00a0al. The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette\u2013Gu\u00e9rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013;190(3):857\u201362. https:\/\/doi.org\/10.1016\/j.juro.2013.03.097. (Epub 20130329. PubMed PMID: 23545101).","journal-title":"J Urol"},{"issue":"1","key":"463_CR57","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11255-021-03073-5","volume":"54","author":"C Rehme","year":"2022","unstructured":"Rehme C, Fritsch B, Thomas L, Istin S, Burchert C, Hummel B, et\u00a0al. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients. Int Urol Nephrol. 2022;54(1):71\u20139. https:\/\/doi.org\/10.1007\/s11255-021-03073-5. (Epub 20211124. PubMed PMID: 34817753; PubMed Central PMCID: PMCPMC8732805).","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"463_CR58","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.clinthera.2016.03.009","volume":"38","author":"AS Pickard","year":"2016","unstructured":"Pickard AS, Jiang R, Lin HW, Rosenbloom S, Cella D. Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer. Clin Ther. 2016;38(4):769\u201377. https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.009. (Epub 20160401. PubMed PMID: 27041407).","journal-title":"Clin Ther"},{"issue":"1","key":"463_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12955-020-01480-3","volume":"18","author":"GA Taarnh\u00f8j","year":"2020","unstructured":"Taarnh\u00f8j GA, Lindberg H, Dohn LH, Omland LH, Hj\u00f8llund NH, Johansen C, et\u00a0al. Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy\u2014a feasibility study. Health Qual Life Outcomes. 2020;18(1):225. https:\/\/doi.org\/10.1186\/s12955-020-01480-3. (Epub 20200711. PubMed PMID: 32653005; PubMed Central PMCID: PMCPMC7353726).","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"463_CR60","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/(sici)1097-0142(19990301)85:5<1186::aid-cncr24>3.0.co;2-n","volume":"85","author":"TR Mendoza","year":"1999","unstructured":"Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et\u00a0al. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer. 1999;85(5):1186\u201396. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19990301)85:5%3c1186::aid-cncr24%3e3.0.co;2-n. (PubMed PMID: 10091805).","journal-title":"Cancer"},{"key":"463_CR61","doi-asserted-by":"publisher","unstructured":"Kamal M, Navai N, Bree KK, Williams LA, Cleeland CS, Shen SE, et al. Validation and application of MD Anderson symptom inventory module for patients with bladder cancer in the perioperative setting. Cancers (Basel). 2022;14(16):1\u201317. https:\/\/doi.org\/10.3390\/cancers14163896. (Epub 20220812. PubMed PMID: 36010890; PubMed Central PMCID: PMCPMC9405694).","DOI":"10.3390\/cancers14163896"},{"key":"463_CR62","doi-asserted-by":"publisher","unstructured":"Wang XS, Bree KK, Navai N, Kamal M, Shen SE, Letona E, et al. Utility of patient-reported symptom and functional outcomes to indicate recovery after first 90 days of radical cystectomy: a longitudinal study. Cancers (Basel). 2023;15(11):1\u201313. https:\/\/doi.org\/10.3390\/cancers15113051. (Epub 20230604. PubMed PMID: 37297013; PubMed Central PMCID: PMCPMC10252507).","DOI":"10.3390\/cancers15113051"},{"issue":"1","key":"463_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-15","volume":"5","author":"CC Gotay","year":"2007","unstructured":"Gotay CC, Pagano IS. Assessment of survivor concerns (ASC): a newly proposed brief questionnaire. Health Qual Life Outcomes. 2007;5(1):15. https:\/\/doi.org\/10.1186\/1477-7525-5-15.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"463_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00520-008-0444-y","volume":"17","author":"S Simard","year":"2009","unstructured":"Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009;17(3):241\u201351. https:\/\/doi.org\/10.1007\/s00520-008-0444-y.","journal-title":"Support Care Cancer"},{"issue":"11","key":"463_CR65","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1002\/pon.4782","volume":"27","author":"JAE Custers","year":"2018","unstructured":"Custers JAE, Kwakkenbos L, van de Wal M, Prins JB, Thewes B. Re-validation and screening capacity of the 6-item version of the cancer worry scale. Psychooncology. 2018;27(11):2609\u201315. https:\/\/doi.org\/10.1002\/pon.4782.","journal-title":"Psychooncology"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00463-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00463-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00463-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:32:12Z","timestamp":1789381932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00463-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00463-6","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ingolf Griebsch is an employee of Ferring Pharmaceuticals, which funded this work; however, Ferring Pharmaceuticals had no role in the design, execution, analysis, or reporting of this systematic review. A.B. owns Bottomley Consulting Group and has undertaken projects funded by pharmaceutical companies; Ferring Pharmaceuticals provided funding to Bottomley Consulting Group for this work. Andrew Bottomley was previously an employee of EORTC and was involved in the development of several EORTC quality of life measures, which are among the instruments evaluated in this review. Sunil Shrestha is an active member of the EORTC quality of life group and is involved in developing several EORTC quality of life measures. Carolyn C. Gotay, John Gore and Fran Curtis have no conflicts of interest to declare. To minimize the risk of bias arising from conflicts of interest, study selection, data extraction, and instrument classification were conducted independently by two reviewers (S.S., A.B.) using prespecified eligibility and tier classification criteria agreed upon prior to data extraction. Authors with declared interests in specific instruments abstained from tier classification decisions regarding those instruments.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review was conducted and reported in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The review protocol was prospectively registered in the international prospective register of systematic reviews (PROSPERO; registration number CRD420251076486) prior to data extraction. As this study involved synthesizing previously published data and did not include primary data collection from human participants, formal ethical approval was not required. All included studies were peer-reviewed publications, and no individual patient data was accessed or analyzed. Data extraction and quality assessment were conducted independently by multiple reviewers to minimize bias and ensure methodological transparency. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}